Human immunodeficiency virus and AIDS: Insights from animal lentiviruses

Journal of Virology

Volumn 74, Issue 16, 2000, Pages 7187-7195

  Miller, R J ^a   Cairns, J S ^a   Bridges, S ^a   Sarver, N ^a  

^a NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

REV PROTEIN; TRANSACTIVATOR PROTEIN; URACIL DNA GLYCOSYLTRANSFERASE; VIF PROTEIN;

ACQUIRED IMMUNE DEFICIENCY SYNDROME; BOVINE IMMUNODEFICIENCY LIKE VIRUS; DISEASE MODEL; FELINE IMMUNODEFICIENCY VIRUS; HUMAN IMMUNODEFICIENCY VIRUS; IMMUNE DEFICIENCY; LENTIVIRINAE; MEDICAL RESEARCH; PRIORITY JOURNAL; SCID MOUSE; SHORT SURVEY; SIMIAN IMMUNODEFICIENCY VIRUS; VIRUS CELL INTERACTION; VIRUS PATHOGENESIS;

ANIMALS; DISEASE MODELS, ANIMAL; GENES, VIRAL; HIV INFECTIONS; HUMANS; LENTIVIRUS; LENTIVIRUS INFECTIONS; RETROVIRIDAE PROTEINS;

EID: 0033858191     PISSN: 0022538X     EISSN: None     Source Type: Journal    
DOI: 10.1128/JVI.74.16.7187-7195.2000     Document Type: Short Survey

References (54)

1. Mutations of RNA and protein sequences involved in human immunodeficiency virus type 1 packaging result in production of noninfectious virus
2. Chemical inactivation of retroviral infectivity by targeting nucleocapsid protein zinc fingers: A candidate SIV vaccine
3. Biological characterization of Rev variation in equine infectious anemia virus
4. Recruitment of a protein complex containing Tat and cyclin T1 to TAR governs the species specificity of HIV-1 Tat
5. Human immunodeficiency virus type 1 Vpr protein binds to the uracil DNA glycosylase DNA repair enzyme
6. The envelope glyco-protein of human immunodeficiency virus type 2 enhances viral particle release: A Vpu-like factor?
7. Human immunodeficiency virus type 1 Vif protein binds to the Pr55(Gag) precursor
8. Natural infection of a homozygous Δ24 CCR5 red-capped mangabey with an R2b-T tropic simian immunodeficiency virus
9. HIV-1 auxiliary proteins: Making connections in a dying cell
10. Demonstration that orf2 encodes the feline immunodeficiency virus transactivating (Tat) protein and characterization of a unique gene product with partial Rev activity
11. Lessons from the cat: Feline immunodeficiency virus as a tool to develop intervention strategies against human immunodeficiency virus type 1
12. HIV-1 regulatory/accessory genes: Keys to unraveling viral and host cell biology
13. PHYLIP - Phylogeny inference package (version 3.2)
14. + cell suppressor factors and cytotoxic T lymphocytes during HIV infection
15. Nuclear import and cell cycle arrest functions of the HIV-1 Vpr protein are encoded by two separate genes in HIV-2/SIV(SM)
16. Noninfectious human immunodeficiency virus type 1 mutants deficient in genomic RNA
17. A consensus sequence for a functional human endogenous retrovirus K (HERV-K) dUTPase
18. Vpx is required for dissemination and pathogenesis of SIV(SM) PBj: Evidence of macrophage-dependent viral amplification
19. Modulation of feline immunodeficiency virus infection by stromal cell-derived factor
20. Anti-HIV agents that selectively target retro-viral nucleocapsid protein zinc fingers without affecting cellular zinc finger proteins
21. Control of RNA initiation and elongation at the HIV-1 promoter
22. Taking a new TAK on Tat transactivation
23. Recrudescence of equine infectious anemia by treatment with immunosuppressive drugs
24. Human immunodeficiency virus type 1 (HIV-1) protein Vif inhibits the activity of HIV-1 protease in bacteria and in vitro
25. Crystal structures of the inactive D30N mutant of feline immunodeficiency virus protease complexed with a substrate and an inhibitor
26. Analysis of the S3 and S3' subsite specificities of feline immunodeficiency virus (FIV) protease: Development of a broad-based protease inhibitor efficacious against FIV, SIV, and HIV in vitro and ex vivo
27. Development of a new type of protease inhibitors, efficacious against FIV and HIV variants
28. Increased mutation frequency of feline immunodeficiency virus lacking functional deoxyuridine-triphosphatase
29. Novel and dynamic evolution of equine infectious anemia virus genomic quasispecies associated with sequential disease cycles in an experimentally infected pony
30. Replication in vitro and in vivo of an equine infectious anemia virus mutant deficient in dUTPase activity
31. + cell anti-HIV activity: Nonlytic suppression of virus replication
32. An endogenous inhibitor of human immunodeficiency virus in human lymphocytes is overcome by the viral Vif protein
33. The mutation rate of human immunodeficiency virus type 1 is influenced by the vpr gene
34. Targeting of the visna virus Tat protein to AP-1 sites: Interactions with the bZIP domains of Fos and Jun in vitro and in vivo
35. Highly potent RANTES analogues either prevent CCR5-using human immunodeficiency virus type 1 infection in vivo or rapidly select for CXCR4-using variants
36. Leptomycin B inhibits equine infectious anemia virus Rev and feline immunodeficiency virus Rev function but not the function of the hepatitis B virus posttranslation regulatory element
37. Immune responses are required to terminate viremia in equine infectious anemia lentivirus infection
38. Visna virus dUTPase is dispensable for neuro-pathogenicity
39. Peptide inhibitors of HIV-1 protease and viral infection of peripheral blood lymphocytes based on HIV-1 Vif
40. Simian immunodeficiency virus replicates to high levels in sooty mangabeys without inducing disease
41. Inhibitors of HIV nucleocapsid protein zinc fingers as candidates for the treatment of AIDS
42. Virus-encoded zinc fingers as targets for antiviral chemotherapy
43. Uracil DNA glycosylase specifically interacts with Vpr of both human immunodeficiency virus type 1 and simian immunodeficiency virus of sooty mangabeys, but binding does not correlate with cell cycle arrest
44. Evidence for a newly discovered cellular anti-HIV-1 phenotype
45. The Vif and Gag proteins of human immunodeficiency virus type 1 colocalize in infected human T cells
46. The regulation of primate immunodeficiency virus infectivity by Vif is cell species restricted: A role for Vif in determining virus host range and cross-species transmission
47. Complementation of vif-defective human immunodeficiency virus type 1 by primate, but not nonprimate, lentivirus vif genes
48. Incorporation of uracil into viral DNA correlates with reduced replication of EIAV in macrophages
49. DUTPase-minus caprine arthritis-encephalitis virus is attenuated for pathogenesis and accumulates G-to-A substitutions
50. Control mechanisms of virus replication in naturally SIVsmm infected mangabeys and experimentally infected macaques
51. A novel CDK9-associated C-type cyclin interacts directly with HIV-1 Tat and mediates its high-affinity, loop-specific binding to TAR RNA
52. Mitogen-activated protein kinase phosphorylates and regulates the HIV-1 Vif protein
53. Regulation of human immunodeficiency virus type 1 infectivity by the ERK mitogen-activated protein kinase-signaling pathway
54. Gag protein epitopes recognized by HLA-A-restricted cytotoxic T lymphocytes from horses with long-term equine infectious anemia virus infection